Instrument Inactif

Autres langues TapImmune Inc. OTC Bulletin Board

Actions

TPIV

US8760334081

Recherche biotechnologique et médicale

Autres langues

22/09	Marker Therapeutics, Inc. Highlights Expanded Manufacturing Capabilities Supporting Mt-601
22/09	Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
14/08	Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
15/05	Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
18/03	Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
18/03	Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
18/03	Marker Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
18/02	Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
26/01	Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
06/01	Marker Therapeutics - Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
05/01	Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
14/11	Marker Therapeutics : Corporate Presentation
14/11	Marker Therapeutics Q3 net loss narrows to $2 mln
14/11	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
13/11	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
05/11	Marker Therapeutics, Inc. Appoints Kathryn Penkus Corzo to Board of Directors, Effective November 1, 2025
05/11	Marker Therapeutics appoints Kathryn Penkus Corzo to board of directors
05/11	Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
03/11	Marker Therapeutics, Inc. Announces Data from Phase 1 APOLLO Study to Present in Two Posters at 67Th American Society of Hematology Annual Meeting and Exposition
03/11	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
06/10/25	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
06/10/25	Marker Therapeutics, Inc. Announces First Patient Treated in Off-The-Shelf Program
28/08/25	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
26/08/25	Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study
26/08/25	Marker Therapeutics : Corporate Presentation